Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center

von der Grün, Jens; Winkelmann, Ria; Rödel, Franz; Balster, Sven; Neumayer, Thomas; Ghanaati, Shahram; Brandts, Christian; Burck, Iris; Martin, Daniel; Rödel, Claus; Kesar, Nikolina; Balermpas, Panagiotis

Abstract: BACKGROUND Salivary gland carcinomas (SGC) cover a heterogeneous group of malignancies with a lack of data of high-level evidence. METHODS Clinical data of 127 patients treated for SGC at a university cancer center between 2002 and 2017 were analyzed retrospectively. The association of clinicopathological characteristics, treatment modalities, adverse events, and outcome was assessed. RESULTS Patients received surgery (n = 65), surgery followed by (chemo-)radiotherapy (n = 56), or primary (chemo-)radiotherapy (n = 6). Injury to the cranial nerves or their branches was the most frequent surgical complication affecting 40 patients (33.1%). Ten year overall and progression-free survival rates were 73.2% and 65.4%, respectively. Parotid tumor site, advanced tumor, and positive nodal stage remained independent negative prognostic factors for overall survival, loco-regional and distant tumor control in multivariate analysis. CONCLUSIONS Optimizing treatment strategies for SGC, depending on distinct clinicopathological factors, remains challenging due to the low incidence rates of the disease.

DOI: https://doi.org/10.1007/s00405-021-06652-5

The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at: von der Grün, Jens; Winkelmann, Ria; Rödel, Franz; Balster, Sven; Neumayer, Thomas; Ghanaati, Shahram; Brandts, Christian; Burck, Iris; Martin, Daniel; Rödel, Claus; Kesar, Nikolina; Balermpas, Panagiotis (2021). Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center. European Archives of Oto-Rhino-Laryngology, 278(11):4411-4421. DOI: https://doi.org/10.1007/s00405-021-06652-5
Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center

Jens von der Grün1,2,3 · Ria Winkelmann4 · Franz Rödel1,2,3,5 · Sven Balster6 · Thomas Neumayer6 · Shahram Ghanaati7 · Christian Brandts2,3,5,8 · Iris Burck9 · Daniel Martin1,2,3,5 · Claus Rödel1,2,3,5 · Nikolina Kesar1 · Panagiotis Balermpas1,10

Received: 7 December 2020 / Accepted: 27 January 2021 / Published online: 24 March 2021 © The Author(s) 2021

Abstract

Background  Salivary gland carcinomas (SGC) cover a heterogeneous group of malignancies with a lack of data of high-level evidence.

Methods  Clinical data of 127 patients treated for SGC at a university cancer center between 2002 and 2017 were analyzed retrospectively. The association of clinicopathological characteristics, treatment modalities, adverse events, and outcome was assessed.

Results  Patients received surgery (n = 65), surgery followed by (chemo-)radiotherapy (n = 56), or primary (chemo-)radiotherapy (n = 6). Injury to the cranial nerves or their branches was the most frequent surgical complication affecting 40 patients (33.1%). Ten year overall and progression-free survival rates were 73.2% and 65.4%, respectively. Parotid tumor site, advanced tumor, and positive nodal stage remained independent negative prognostic factors for overall survival, loco-regional and distant tumor control in multivariate analysis.

Conclusions  Optimizing treatment strategies for SGC, depending on distinct clinicopathological factors, remains challenging due to the low incidence rates of the disease.

Keywords  Salivary gland carcinoma · Head and neck cancer · Surgery · Radiotherapy · Patterns of care

Introduction

Salivary gland carcinomas (SGC) account for 1–6% of all head and neck tumors and comprise a variety of 20 different histological subtypes as classified by the World Health Organization (WHO) in 2017 [1, 2]. Some of those subtypes are extremely rare, which prohibits clinical trials being...
conducted, and thus the development of evidence-based guidelines for treatment standardization [1]. Seventy percent of SGC arise from the parotid gland, while 20–25% derive from the submandibular and sublingual glands. Whereas acinic cell carcinoma (ACC, 15–17%), adenoid cystic carcinoma (AdCC, 16–27%) and mucoepidermoid carcinoma (MEC, 15–38%) represent frequent histopathological entities in the paired, major salivary glands, AdCC and MEC are also common in the minor salivary glands of the oral cavity [3]. While ACC depicts a low-risk malignancy, other histopathological subtypes such as AdCC, salivary duct carcinoma (SDC), or adenocarcinoma—not otherwise specified (ACA) are high-risk tumors with different prognosis [1]. By actual guidelines [4], surgical resection is the standard treatment for SGC including neck dissection (ND) in case of adverse features such as advanced tumor stages (T3–T4) and/or clinically positive lymph nodes of the neck. A common therapeutic challenge, even for high-volume centers, are the positive resection margins often described in the literature, which often lead to the decision for adjuvant/additive treatment [5–7]. Postoperative radiotherapy (PORT) is recommended in case of adverse pathological features (e.g., advanced tumor stages T3–T4, positive resection margins), and AdCC [8]. Various irradiation modalities have been used in the past, including particle-radiotherapy characterized by a high linear energy transfer (LET) and relative biological efficacy (RBE), with heavy ions and neutrons showing some promising results even for radioresistant histopathological entities [9, 10]. Due to the lack of prospective, randomized clinical trials, the benefit of multimodal protocols has not been proven, yet. Data on the efficiency of chemotherapy (CTX), targeted therapy, and immunotherapy for SGC are rare, and so far, without prospective evidence for improved outcome [8, 11–14]. This study aims to analyze patterns of care and the efficacy of surgery, radiotherapy (RT), and chemoradiotherapy (CRT) as single or combined modalities in the treatment of SGC with a focus on the outcome and adverse events from a longstanding experience of a university cancer center.

Patients and methods

Patient cohort and tumor staging

Clinical records of 127 patients, treated for primary or recurrent SGC between 2002 and 2017 at the Departments of Otorhinolaryngology, Oral, Maxillofacial and Facial Plastic Surgery, and Radiotherapy and Oncology at the University Hospital Frankfurt, Germany were analyzed retrospectively following institutional ethics board approval (No. 30/17, Ethics Committee, University Hospital Frankfurt, Germany) in accordance with the Declaration of Helsinki. Patients provided written informed consent for scientific use of their pseudonymized data and biomaterial. Routine pretherapeutic staging included physical examination, computed tomography/magnetic resonance imaging (CT/MRI) of the head and neck, biopsy and either CT of the thorax and abdomen, or chest radiography and abdomen sonography prior to treatment. All cases were discussed at an interdisciplinary organized tumor board of the head and neck specialties (otorhinolaryngology, oral and maxillofacial surgery, radiation oncology, medical oncology, pathology, radiology), and all patients provided written informed consent for their individual designated treatment.

Current literature distinguishes between high- and low-risk SGC. Based on this categorization, the tumors of this cohort were also divided into these two groups. The high-risk tumor subgroup comprised ACA, AdCC, SDC, squamous cell carcinoma (SCC), MEC G3, carcinoma ex pleomorphic adenoma, and oncocytic carcinoma. The low-risk tumor subgroup consisted of ACC, MEC G1/G2, polymorphous adenocarcinoma, epithelial–myoepithelial carcinoma, myoepithelial carcinoma, clear cell carcinoma, and basal cell adenocarcinoma [1, 15].

In case of patients with SCC, the final diagnosis was made upon exclusion of any other primary tumor site, including clinical examination, specifically dermatological inspection, and radiological examination. If no squamous cell primary was detectable after thorough staging, the cases were included in the present analysis, as the treatment was identical to primary parotidal malignancies.

Treatment protocols

Surgical procedures included tumor resection, whereas ND was conducted for advanced tumor stages (T3–T4), and/or clinically positive lymph nodes of the neck. As mentioned before by Quer et al. [16], total parotidectomy in this study was defined as parotidectomy with preservation of the facial nerve, whereas radical parotidectomy included parotidectomy with sacrifice of the facial nerve. As further reported by previous studies, in some cases, the probability of occult cervical lymph node metastases might be given in up to 31.2% [17]. Thus, the option of elective ND in T1N0- and T2N0-staged patients was critically discussed with each of the respective individuals.

RT was delivered either as three-dimensional conformal radiotherapy (3D-RT), or, since 2010, as intensity-modulated radiotherapy (IMRT), both under image guidance, implementing portal imaging and/or conebeam CT scans. Each patient received a planning CT and thermoplastic masks were used for immobilization during irradiation (photon energy: 6 MV). The planned target volumes (PTV) included elective irradiation of the draining cervical lymph nodes up to 50–54 Gy, dose escalation up to 58–60 Gy.
for involved lymph node levels, and a boost to the primary tumor region with a median total reference dose of 64–66 Gy for PORT and postoperative chemoradiotherapy (POCRT), and 70–72 Gy for definitive treatment. PORT or POCR was applied to patients with adverse pathological features, such as G3 histology, advanced tumor stages (T3–T4), positive lymph nodes, positive resection margins, neural/perineural invasion, and lymphatic/vascular invasion.

Concomitant CRT was only applied in case of loco-regionally advanced ACA or SCC with additional risk factors such as close or positive resection margins and extra-nodal extension. Acute toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute, Bethesda, MD, USA in their, respectively, current version by the time of treatment. Due to the retrospective character of the analysis and scarce documentation of late toxicities, the latter were not considered further throughout the study. Follow-up appointments, including clinical examination, CT/MRI scans of the head and neck, as well as additional biopsy in case of suspicious findings were scheduled every 3 months for the first 2 years, and every 6 months thereafter for a total of 5 years.

Statistical analysis

Statistical analyses were performed using SPSS (IBM SPSS Statistics, v24.0, Armonk, NY, USA) and R (The R Foundation for Statistical Computing, v3.5.0, Vienna, Austria). The main oncological outcome measures were overall survival (OS), loco-regional progression-free survival (LPFS), distant metastases-free survival (DMFS), and progression-free survival (PFS). The endpoints since the date of diagnosis were set as the occurrence of the respective event or death from any cause, while patients, who were alive and/or event-free, were censored at the last contact. The log-rank test was used with respect to univariate analyses, whereas the Cox model was applied considering multivariate analyses. Variables that were evaluated significant in the univariate model were forwarded to the multivariate one in a single step, following the Schoenfeld test for proportional hazards. To avoid overfitting [18], we aimed for a minimum of ten events per variable in multivariate analysis. Accordingly, age as a multi-influenced variable and any non-categorial variable with an obvious influence on survival endpoints were excluded a priori from the Cox model. Additionally, differences between categorial variables were assessed by the Pearson chi-squared test. Survival curves were visualized by the Kaplan–Meier method. Statistical significance was considered at \( p \leq 0.05 \).

Results

Clinicopathological characteristics and outcome

Sixty-nine out of 127 patients (54.3%) were male, and the overall median age was 61 years at the time of diagnosis. The majority of the SGC were located in the parotid gland (72.4%), followed by 18.1% in the minor salivary glands. Details on initial tumor stages, resection margins, treatment modalities, and histopathological entities are shown in Table 1.

The median overall follow-up period was 55 months (range: 0–443 months) and reached 74 months (range: 1–443 months) in patients who were alive by the time of their last visit. Until the end of follow-up, 17.3% of the patients alive developed loco-regional recurrences and 17.3% of the surviving patients were diagnosed with distant metastases (Fig. 1). Median OS since the date of primary diagnosed loco-regional recurrence or distant metastases was 28.5 months (range: 0–233 months) and 21.5 months (range: 1–130 months), respectively.

Treatment procedures and adverse events

A total of 121 patients (95.3%) received surgery of whom 84 individuals (69.4%) were treated by parotidectomy. Sixty-eight patients (56.2%) received at least ipsilateral ND, whereas bilateral ND was performed predominantly in patients with midline crossing tumors.

Injury to the cranial nerves (V, VII, X, XI, and XII) or their branches of any severity grade, as classified by Seddon and Sunderland [19, 20], was the most frequent surgical complication affecting a total of 40 patients (33.1%) at follow-up. Particularly, iatrogenic facial nerve damage or sacrifice within the scope of radical parotidectomy represented the most common (n = 32, 80.0%) of all neurological complications. Reconstructive surgery and symptomatic treatment of facial nerve palsy included local and/or distant nerve graft transfer (n = 3), primary nerve coadaptation (n = 2), upper eyelid gold weight placement (n = 3), tarsorrhaphy (n = 2), and/or lateral tarsal strip procedure (n = 1). Due to the retrospective character of our study, a detailed re-assessment on the extent of facial nerve involvement and hence a rating according to the scale by House and Brackmann was not possible [21]. Wound healing disorders occurred in six patients (5.0%), including wound dehiscence, fistula, and Frey’s syndrome (n = 2 each), while postoperative hemorrhage was observed in three patients (2.5%) (Table 2). However, the addition of ND to surgery was well tolerated and did not increase the surgical complication rate compared to tumor resection alone (p = 0.069).
Overall RT completion rate reached 98.4%. A single patient refused to continue PORT at 11.94 Gy of the prescribed 64.02 Gy without experiencing any adverse events. Irradiation was applied by photon therapy for the vast majority of patients \((n=53)\), the median applied dose to the primary tumor region was 64.8 Gy regarding PORT and 64.0 Gy regarding POCRT.

CTX regimens in case of the 13 patients receiving POCRT comprised cisplatin and 5-fluorouracil \((n=7)\), carboplatin and 5-FU \((n=1)\), cisplatin monotherapy \((n=1)\), 5-FU monotherapy \((n=3)\) and one unknown CTX regimen as treated prior to referral. There was no difference regarding oncological outcome comparing PORT with POCRT \((\text{OS}: p = 0.236, \text{LPFS: } p = 0.609, \text{DMFS: } p = 0.277; \text{data not shown})\). A single patient treated by primary CRT received cisplatin and 5-FU. The only common grade ≥ II toxicities observed after RT was dermatitis and mucositis in the majority of the irradiated patients, amounting to 8.1% (grade ≥ III 1.6%) and 19.4% (grade ≥ III 1.6%), respectively, whereas leukocytopenia grade ≥ III in 15.4% was the most relevant adverse event of the patients treated with concomitant CTX. Neither grade IV adverse events nor patient deaths related to RT/CRT occurred (Supplementary Table 1).

### Table 1 Clinicopathological characteristics

| Clinicopathological characteristics | \(n\) (%) |
|-------------------------------------|-----------|
| Total                               | 127 (100.0) |
| Gender                              |           |
| Male                                | 69 (54.3)  |
| Female                              | 58 (45.7)  |
| Age\(^a\)                           |           |
| < Median                            | 62 (48.8)  |
| ≥ Median                            | 65 (51.2)  |
| Tumor site                          |           |
| Parotid gland                       | 92 (72.4)  |
| Submandibular gland                 | 10 (7.9)   |
| Sublingual gland                    | 21 (1.6)   |
| Minor salivary glands               | 23 (18.1)  |
| T-stage                             |           |
| T1                                  | 44 (37.6)  |
| T2                                  | 17 (14.5)  |
| T3                                  | 31 (26.5)  |
| T4                                  | 25 (21.4)  |
| Missing values                      | 10        |
| N-stage                             |           |
| N0                                  | 84 (66.1)  |
| N1                                  | 18 (14.2)  |
| N2                                  | 24 (18.9)  |
| N3                                  | 1 (0.8)    |
| M-stage                             |           |
| M0                                  | 108 (85.0) |
| M1                                  | 4 (3.1)    |
| MX\(^b\)                            | 15 (11.8)  |
| Resection margins                   |           |
| R0                                  | 77 (63.6)  |
| R1                                  | 37 (30.6)  |
| R2                                  | 7 (5.8)    |
| No surgery                          | 6         |
| Treatment modalities                |           |
| Surgery alone                       | 62 (48.8)  |
| Neoadjuvant chemotherapy\(^c\) and surgery | 3 (2.4)  |
| Neoadjuvant chemotherapy\(^d\) and surgery followed by radiotherapy | 2 (1.6) |
| Surgery followed by radiotherapy    | 41 (32.3)  |
| Surgery followed by chemoradiotherapy | 13 (10.2) |
| Primary radiotherapy                | 5 (3.9)    |
| Primary chemoradiotherapy           | 1 (0.8)    |
| Carcinoma histology                 |           |
| Acinic cell                         | 12 (9.4)   |
| Mucoepidermoid G1/G2                | 20 (15.7)  |
| Mucoepidermoid G3                   | 2 (1.6)    |
| Adenoid cystic                      | 24 (18.9)  |
| Polymorphous adeno                  | 2 (1.6)    |
| Epithelial–myoepithelial            | 4 (3.1)    |
| Clear cell                          | 1 (0.8)    |
| Basal cell adeno                    | 4 (3.1)    |

\(^a\)Age: median 61 years, range 9–93 years

\(^b\)MX was defined as any suspect radiographic finding requiring process control

\(^c\)TPF (docetaxel, cisplatin, 5-fluorouracil), \(n=2\); missing information on sequence and agent, \(n=1\)

\(^d\)TPF (docetaxel, cisplatin, 5-fluorouracil), \(n=2\)

The association of clinicopathological characteristics and treatment modalities is shown in Supplementary Table 2. Based on the treatment patterns and the most common procedures applied in our patient cohort, we reconstructed a fluxogram (Fig. 2), which was found to be in accordance with the most recent version of the National Comprehensive Cancer Network (NCCN) guidelines for these malignancies [4].
Tumors of the parotid and submandibular glands were treated more often by surgery to both the primary and the neck than tumors arising from the sublingual gland and minor salivary glands \((p = 0.018)\). Nevertheless, additional treatment by PORT/POCRT was not influenced by the tumor site \((p = 0.566)\).

Patients with loco-regionally advanced \((p = 0.011)\) and high-risk tumors \((p < 0.001)\), nodal involvement \((p = 0.009)\), and positive resection margins \((p = 0.004)\) received surgery and PORT/POCRT more often (Supplementary Table 2).

Impact of tumor site and histopathology on initial tumor stage

Tumors of the parotid gland were more common in older patients \((p = 0.006)\). Furthermore, their resection was more often associated with ND \((p = 0.008)\). Also, the histopathological subtypes were heterogeneously distributed between the different salivary glands \((p = 0.001)\) (Supplementary Table 3).

Regarding the five most frequently occurring histopathological subtypes within the cohort, the diagnosis of ACA and SCC was associated with higher age \((p < 0.001)\), as well as with advanced tumor \((p < 0.001)\), and nodal stage \((p < 0.001)\) (Supplementary Table 4).

Impact of clinicopathological characteristics on outcome

In univariate analysis, higher age, primary tumor location within the parotid gland, tumor histopathology, advanced tumor and positive nodal stage, as well as positive resection margins were associated with impaired oncological outcome in terms of OS, LPFS, DMFS and PFS. Furthermore, adjuvant RT was associated with poor DMFS and PFS. Tumor site (parotid gland), advanced tumor and positive nodal stage remained independent prognostic factors in multivariate analysis regarding reduced OS, PFS, LPFS, and DMFS (Table 3).

Fig. 1 Oncological outcome of total cohort. Abbreviations: OS overall survival, PFS progression-free survival, LPFS loco-regional progression-free survival, DMFS distant metastases-free survival
Discussion

To date, only a few large retrospective studies regarding the treatment of SGC have been published and to the best of our knowledge, there are no prospective trials reporting results on primary treatment modalities including surgery or radiotherapy. Besides, most of the retrospective trials either report on major or minor salivary glands or distinct histopathological subtypes, exclusively [5, 22–25].

The current study provides comprehensive data on the long-term outcome with a median follow-up period of 55 and 74 months for those patients who were alive by the time of their last appointment. We consider this to be a major strength of the study, as long-term follow-up has been recommended to detect local recurrences or metastases occurring beyond 60 months after initial treatment [26]. Furthermore, to prevent selection bias, all treated patients presented in the cancer center during the period analyzed were included in analysis.

The cohort of patients enrolled is largely heterogeneous, as expected for this diagnosis, however, representative of the daily clinical practice in a large university cancer center. The median age by the time of initial tumor diagnosis and the slight predominance of the male gender is in accordance with two large retrospective cohorts encompassing different entities of SGC, reporting overall median ages of 58 and 63 years and proportions of male patients to be 52.0% and 58.5%, respectively [6, 7]. Similar to one of the largest studies on SGC by Terhaard et al. on behalf of the Dutch Head and Neck Oncology Cooperative Group retrospectively

Table 2  Applied surgical techniques and coinciding peri- and postoperative complications

| Surgical techniques                        | n (%) |
|-------------------------------------------|-------|
| Treated patients                          | 121 (100.0) |
| Main procedure                            |       |
| Lateral (≈ superficial) parotidectomy     | 14 (11.6) |
| Total parotidectomy                       | 36 (29.8) |
| Radical parotidectomy                     | 12 (9.9) |
| Parotidectomy, not specified              | 22 (18.2) |
| Submandibular sialadenectomy              | 11 (9.1) |
| Sublingual sialadenectomy                 | 1 (0.8) |
| Local resection                           | 16 (13.2) |
| Resection including partial maxillectomy   | 6 (5.0) |
| Resection including partial mandibulectomy | 3 (2.5) |
| Management of the neck                    |       |
| Ipsilateral neck dissection                | 68 (56.2) |
| Bilateral neck dissection                  | 12 (9.9) |
| Neck dissection, not specified             | 12 (9.9) |
| None                                       | 29 (24.0) |
| Surgical complications                     |       |
| Treated patients                          | 121 (100.0) |
| Injury to the cranial nerves or their branches |       |
| Yes, including                            | 40 (33.1) |
| Facial nerve (V)                          | 2 (5.0) |
| Recurrent laryngeal nerve (X)              | 32 (80.0) |
| Accessory nerve (XI)                      | 1 (2.5) |
| Hypoglossal nerve (XII)                   | 1 (2.5) |
| No                                        | 81 (66.9) |
| Postoperative hemorrhage                   |       |
| Yes                                       | 3 (2.5) |
| No                                        | 118 (97.5) |
| Wound-healing disorder                     |       |
| Yes                                       | 6 (5.0) |
| No                                        | 115 (95.0) |
including 565 patients [7], and a follow-up study by Westergaard-Nielsen et al. including 1601 SGC patients [27], the tumors in our cohort were more likely to be diagnosed at T1/T2-stage and N0-stage without signs of distant metastases. Furthermore, in this cohort, AdCC, ACA and MEC were the predominant histological subtypes, in accordance with the literature [7]. Interestingly, the percentage of SCC in our cohort is 11.8% and higher compared to previous reports (4%) [1, 28], so that false clinical diagnosis as an SGC primary instead of metastasis from other tumors at least for a part of these cases cannot be ruled out. Primary SCC of the salivary glands, mostly arising from Stensen’s and Wharton’s ducts is mostly caused by chronic inflammation as result of e.g., chronic sialolithiasis and has been described before [1].

Complete tumor resection in our study was achieved in 63.6% of the cases, slightly more often than reported by Terhaard et al. where complete primary tumor resection was achieved in 59% of the cases [7]. Incomplete primary tumor resection is not uncommon and complete resection rates as low as 31.3% have been reported even for experienced and high-volume centers [5, 6]. Parotid tumors in this study were more often diagnosed at advanced patient age (p = 0.006). ACA and SCC occurred more often in the parotid glands and their diagnosis has been associated with higher age before [7].

Ten year OS rate was 73.2% in our cohort, which is higher as reported in literature ranging from 43 to 52% [5–7, 25, 27, 29, 30]. Independent prognostic factors for OS in the present study were parotid tumor site, advanced T- and positive N-stage. Yet, tumor site has been associated with OS in multivariate analysis by other authors as well [7, 31]. Moreover, similar to our data, Bjørndal et al. stressed the prognostic importance of tumor stage for recurrence and survival [30]. Possible explanations for the higher OS rate in our cohort might be the inclusion of predominantly high-risk subtypes by other authors [25], or older patient series ranging back to the 1940s with a lack of modern diagnostic imaging using different RT techniques [5–7, 29].

Primary RT/CRT was performed when patients were ineligible for primary surgery. A review by Wang et al. revealed significant impairment of OS for primary RT when compared to PORT in five series with a total of 913 patients [8]. Due to patients’ risk profiles, ND was more often performed for parotid gland tumors than for other tumor locations (p = 0.008). Performing ND did not have a significant impact on OS. POCRT in this series was applied in cases of loco-regionally advanced ACA or SCC with additional risk factors like close or positive resection margins and extra-nodal extension and concomitant CTX was platinum-based in combination with 5-FU in most cases. Despite the unfavorable tumor characteristics outcome was not impaired for these patients when compared to the group receiving only PORT. Indeed, from the cytotoxic regimens tested with or without RT for SGC, cisplatin and 5-FU were shown to be amongst the most efficient agents within various small
Table 3 Prognostic factors for overall, loco-regional progression-free, distant metastases-free and progression-free survival

| Clinicopathological characteristics | Univariate analysis | Schoenfeld test | Multivariate analysis |
|-------------------------------------|---------------------|-----------------|----------------------|
|                                     | $p$                 | $p$             | Hazard ratio | 95% Confidence interval | $p$ |
| Overall survival ($n = 36$ events included into multivariate analysis) |                     |                 |             |                            |    |
| Gender (male vs. female)            | 0.188               | 0.108 (global)  |             |                            |    |
| Age$^a$ (< median vs. ≥ median)     | $<0.001$            |                 |             |                            |    |
| Tumor site (parotid gland vs. other)| 0.007               | 0.389           | 0.301       | 0.110–0.825                | 0.020 |
| Histology (low-risk vs. high-risk)  | 0.001               |                 |             |                            |    |
| T-stage (T1–T2 vs. T3–T4)          | $<0.001$            | 0.536           | 5.476       | 2.297–13.054               | $<0.001$ |
| N-stage (N0 vs. N1–N3)             | $<0.001$            | 0.659           | 3.067       | 1.462–6.431                | 0.003 |
| Resection margins (R0 vs. other)   | 0.001               | 0.229           | 1.574       | 0.792–3.132                | 0.196 |
| Surgery (with neck dissection vs. without neck dissection) | 0.603               |                 |             |                            |    |
| Adjuvant radiotherapy (yes vs. no) | 0.141               |                 |             |                            |    |
| Loco-regional progression-free survival ($n = 44$ events included into multivariate analysis) |                     |                 |             |                            |    |
| Gender (male vs. female)            | 0.194               | 0.684 (global)  |             |                            |    |
| Age$^a$ (< median vs. ≥ median)     | $<0.001$            |                 |             |                            |    |
| Tumor site (parotid gland vs. other)| 0.001               | 0.992           | 0.180       | 0.065–0.501                | 0.001 |
| Histology (low-risk vs. high-risk)  | 0.005               | 0.607           | 1.038       | 0.397–2.712                | 0.940 |
| T-stage (T1–T2 vs. T3–T4)          | $<0.001$            | 0.646           | 5.206       | 2.383–11.373               | $<0.001$ |
| N-stage (N0 vs. N1–N3)             | $<0.001$            | 0.637           | 2.528       | 1.194–5.352                | 0.015 |
| Resection margins (R0 vs. other)   | 0.009               | 0.094           | 1.121       | 0.588–2.134                | 0.729 |
| Surgery (with neck dissection vs. without neck dissection) | 0.431               |                 |             |                            |    |
| Adjuvant radiotherapy (yes vs. no) | 0.097               |                 |             |                            |    |
| Distant metastases-free survival ($n = 40$ events included into multivariate analysis) |                     |                 |             |                            |    |
| Gender (male vs. female)            | 0.096               | 0.190 (global)  |             |                            |    |
| Age$^a$ (< median vs. ≥ median)     | $<0.001$            |                 |             |                            |    |
| Tumor site (parotid gland vs. other)| 0.006               | 0.870           | 0.313       | 0.116–0.846                | 0.022 |
| Histology (low-risk vs. high-risk)  | $<0.001$            | 0.018           |             |                            |    |
| T-stage (T1–T2 vs. T3–T4)          | $<0.001$            | 0.698           | 5.053       | 2.201–11.601               | $<0.001$ |
| N-stage (N0 vs. N1–N3)             | $<0.001$            | 0.446           | 3.718       | 1.773–7.794                | 0.001 |
| Resection margins (R0 vs. other)   | 0.001               | 0.102           | 1.572       | 0.814–3.034                | 0.178 |
| Surgery (with neck dissection vs. without neck dissection) | 0.456               |                 |             |                            |    |
| Adjuvant radiotherapy (yes vs. no) | 0.024               | 0.414           | 1.247       | 0.616–2.524                | 0.540 |
| Progression-free survival ($n = 46$ events included into multivariate analysis) |                     |                 |             |                            |    |
| Gender (male vs. female)            | 0.108               | 0.741 (global)  |             |                            |    |
| Age$^a$ (< median vs. ≥ median)     | $<0.001$            |                 |             |                            |    |
| Tumor site (parotid gland vs. other)| 0.001               | 0.956           | 0.193       | 0.071–0.529                | 0.001 |
| Histology (low-risk vs. high-risk)  | 0.002               | 0.764           | 1.092       | 0.421–2.831                | 0.857 |
| T-stage (T1–T2 vs. T3–T4)          | $<0.001$            | 0.497           | 4.583       | 2.158–9.733                | $<0.001$ |
| N-stage (N0 vs. N1–N3)             | $<0.001$            | 0.706           | 2.857       | 1.348–6.055                | 0.006 |
| Resection margins (R0 vs. other)   | 0.007               | 0.110           | 1.182       | 0.629–2.223                | 0.603 |
| Surgery (with neck dissection vs. without neck dissection) | 0.359               |                 |             |                            |    |
| Adjuvant radiotherapy (yes vs. no) | 0.044               | 0.380           | 1.125       | 0.587–2.160                | 0.722 |

$^a$Age: median 61 years, range 9–93 years; factor was excluded a priori from multivariate analysis as a multi-influenced variable
patient series for locally advanced or recurrent/metastatic disease [8, 11]. While some authors reported good local control rates for POCRT, Hsieh et al. reported improved local control rates for POCRT (n = 58) in comparison to PORT (n = 33) [32–34]. However, a SEER—Surveillance, Epidemiology, and End Results—Medicare database analysis revealed increased mortality and toxicity for the concomitant POCRT when compared to PORT alone [35]. Due to heterogeneous patient cohorts and individual indications for POCRT, interpretation of such data remains difficult. Taken together, no evidence exists for an additional benefit of CTX in terms of tumor site, histopathological entities and treatment hamper comparability and the derivation of treatment recommendations. Third, low patient numbers for rare tumor entities. Fourth, the pathological parameters vascular and lymphatic invasion, perineural invasion as well as extra-nodal extension were not analyzed. Fifth, possible referral bias. Sixth, the inclusion of some very advanced/palliative cases, which might have distorted the results. Although there are limitations to this study as mentioned before, this is one of the most recent series regarding the treatment of SGC from a tertiary tumor center, implementing all current techniques of surgery and radiotherapy with a comparably long follow-up period.

Conclusions

SGC are a heterogeneous group of carcinomas with varying outcome depending on factors such as primary tumor site and tumor stage. Optimizing multimodal treatment strategies for distinct histological entities, tumor localizations, and stages remains challenging due to low incidence rates. Radical surgery remains the mainstay of treatment, followed by radiotherapy in case of adverse pathological features, and results in fairly good survival rates, at least in high-volume centers. The role of chemotherapy remains controversial. However, to further improve outcome and reduce toxicities, prospective clinical trials are warranted. Large, international, prospective registers and systematic retrospective meta-analyses are necessary for overcoming recruiting problems for the rarest entities.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00405-021-06652-5.

Acknowledgements

This work was supported by grants from the Else Kröner-Fresenius-Stiftung to Jens von der Grün.

Author contributions

JvdG, NK and PB: data acquisition, analysis, data interpretation, paper writing, paper revision and finalization. RW and FR: analysis, data interpretation, paper writing, paper revision and finalization. SB, TN, SG, IB and CB: data acquisition, analysis, data interpretation, paper revision and finalization. All authors have approved the submitted current version of this paper.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
Compliance with ethical standards

Conflict of interest The authors have no relevant financial or non-financial interests to disclose.

Ethics approval This retrospective analysis was approved by the institutional ethics board of the University Hospital Frankfurt, Germany (No. 30/17).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds) (2017) WHO classification of head and neck tumours, 4th ed. World Health Organization Classification of Tumours, Ninth International Agency for Research on Cancer (IARC), Lyon, France, pp 159–183
2. Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24(17):2673–2678. https://doi.org/10.1200/JCO.2005.05.3025
3. Vander Poorten V, Meulemans J, Delaere P, Nuyts S, Clement P (2020) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Laryngoscope 119(7):1334–1338. https://doi.org/10.1002/lary.20501
4. Cianchetti M, Sandow PS, Scarborough LD, Morris CG, Kirwan J, Werning JW, Mendenhall WM, Morris CG, Amgdur RJ, Werning JW, Villaret DB (2005) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103(12):2544–2550. https://doi.org/10.1002/cncr.21083
5. Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, Tjio-Heslinga RE, de Jong JM, Roedenburg JL, Dutch H, Neck Oncology Cooperative G (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26(8):681–692; discussion 692–683. https://doi.org/10.1002/hed.10400
6. Wang X, Luo Y, Li M, Yan H, Sun M, Fan T (2017) Management of salivary gland malignancies—a review. Oncotarget 8(3):3946–3956
7. Timoshchuk MA, Dekker P, Hippe DS, Parvathaneni U, Liao JJ, Laramore GE, Dillon JK (2019) The efficacy of neutron radiation therapy in treating salivary gland malignancies. Oral Oncol 88:51–57. https://doi.org/10.1016/joraloncol.2018.11.006
8. Wang X, Luo Y, Li M, Yan H, Sun M, Fan T (2017) Management of salivary gland malignancies—a review. Oncotarget 8(3):3946–3956
9. Timoshchuk MA, Dekker P, Hippe DS, Parvathaneni U, Liao JJ, Laramore GE, Dillon JK (2019) The efficacy of neutron radiation therapy in treating salivary gland malignancies. Oral Oncol 88:51–57. https://doi.org/10.1016/joraloncol.2018.11.006
10. Jensen AD, Poulaakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, Freier K, Krauss J, Hoss A, Haberer T, Jakel O, Munter MW, Schulz-Ertner D, Huber PE, Debus J (2016) High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years’ experience with raster-scanned carbon ion therapy. Radiother Oncol 118(2):272–280. https://doi.org/10.1016/j.radonc.2015.05.010
11. Lagha A, Chraiet N, Ayadi M, Krimi S, Allani B, Rif H, Raies H, Mezlini A (2012) Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol 4:19. https://doi.org/10.1186/1758-3284-4-19
12. Fayette J, Even C, Digue L, Geoffrois L, Rolland F (2019) NIS-CAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic adenosquamous carcinoma (R/M ACC). J Clin Oncol 37(suppl: abstr 6083)
13. Tchekmedyan V, Sherman EJ, Dunn L, Betten JV, Michel LS, Kriplani A (2019) A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenosquamous carcinoma (R/M ACC). J Clin Oncol 37(suppl: abstr 6084)
14. Vital D, Ikenberg K, Moch H, Rossle M, Huber GF (2019) The expression of PD-L1 in salivary gland carcinomas. Sci Rep 9(1):12724. https://doi.org/10.1038/s41598-019-49215-9
15. Seethala RR (2009) An update on grading of salivary gland carcinomas. Head Neck Pathol 3(1):69–77. https://doi.org/10.1007/s12198-009-0102-9
16. Quer M, Guntinas-Lichius O, Marchal F, Vander Poorten V, Chevalier D, Leon X, Eisele D, DulgueroP (2016) Classification of parotidectomies: a proposal of the European Salivary Gland Society. Eur Arch Otorhinolaryngol 273(10):3307–3312. https://doi.org/10.1007/s00405-016-3916-6
17. Stodulski D, Mikaszewski B, Majewska H, Wisniewski P, Stankiewicz C (2017) Probability and pattern of occult cervical lymph node metastases in primary parotid carcinoma. Eur Arch Otorhinolaryngol 274(3):1659–1664. https://doi.org/10.1007/s00405-016-4407-5
18. Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48(12):1503–1510. https://doi.org/10.1016/0895-4356(95)00048-8
19. Seddon HJ (1943) Three types of nerve injury. Brain 66(4):237–288. https://doi.org/10.1093/brain/66.4.237
20. Sunderland S (1951) A classification of peripheral nerve injuries producing loss of function. Brain 74(4):491–516. https://doi.org/10.1093/brain/74.4.491
21. House JW, Brackmann DE (1985) Facial nerve grading system. Otolaryngol Head Neck Surg 93(2):146–147. https://doi.org/10.1177/019459988509300220
22. Storey MR, Garden AS, Morrison WH, Eicher SA, Schechter NR, Ang KK (2001) Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 51(4):952–958. https://doi.org/10.1016/S0360-3016(01)01724-2
23. North CA, Lee DJ, Piantadosi S, Zahurak M, Johns ME (1990) A proposed radiation therapy for adenoid cystic carcinoma of the head and neck. J LaryngolOtol 104(1):1272–1299. https://doi.org/10.1016/0360-3016(90)90304-3
24. Mendenhall WM, Morris CG, Amgdur RJ, Werning JW, Hinerman RW, Villaret DB (2004) Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 26(2):154–162. https://doi.org/10.1002/hed.10380
25. Iseli TA, Karnell LH, Graham SM, Funk GF, Buatti JM, Gupta AK, Robinson RA, Hoffman HT (2009) Role of radiotherapy in adenoid cystic carcinoma of the head and neck. J LaryngolOtol
26. Jones AS, Beasley NJP, Houghton DJ (1998) Tumours of the
minor salivary glands. ClinOtolaryngol 23:27–33
27. Westergaard-Nielsen M, Godballe C, Eriksen JG, Larsen SR,
Kiss K, Agander T, Ulhøi BP, Charabi B, Klug TE, Jacobsen H,
Johansen J, Kristensen CA, Andersen E, Andersen M, Madsen S,
Bjørndal K (2020) Salivary gland carcinoma in Denmark: a
national update and follow-up on incidence, histology, and
outcome. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/
S00405-020-06205-2
28. Ho K, Lin H, Ann DK, Chu PG, Yen Y (2011) An overview of
the rare parotid gland cancer. Head Neck Oncol 3(1):40. https://
doi.org/10.1186/1758-3284-3-40
29. Renehan A, Gleave EN, Hancock BD, Smith P, McGurk M (1996)
Long-term follow-up of over 1000 patients with salivary gland
tumours treated in a single centre. Br J Surg 83(12):1750–1754.
https://doi.org/10.1002/bjs.1800831228
30. Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen
J, Kristensen CA, Homoe P, Sorensen CH, Andersen E, Bund-
gaard T, Primdahl H, Lamberts K, Andersen LJ, Godballe C
(2012) Salivary gland carcinoma in Denmark 1990–2005: out-
come and prognostic factors. Results of the Danish Head and Neck
Cancer Group (DAHANCA). Oral Oncol 48(2):179–185. https://
doi.org/10.1016/j.oraloncology.2011.09.005
31. Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen
HS (1998) Salivary gland carcinomas—prognostic factors. Acta
Oncol 37(7–8):701–713. https://doi.org/10.1080/0284186984
30089
32. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Por-
tugal L, Seiwert T, Villalflor VM, Cohen EE, Vokes EE, Blair EA
(2011) Adjuvant chemoradiotherapy for locoregionally advanced
and high-risk salivary gland malignancies. Head Neck Oncol 3:31.
https://doi.org/10.1186/1758-3284-3-31
33. Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR,
Balboni TA, Tishler RB (2012) Salivary gland tumors treated with
adjuvant intensity-modulated radiotherapy with or without con-
current chemotherapy. Int J Radiat Oncol Biol Phys 82(1):308–
314. https://doi.org/10.1016/j.ijrobp.2010.09.042
34. Hsieh CE, Lin CY, Lee LY, Yang LY, Wang CC, Wang HM,
Chang JT, Fan KH, Liao TC, Yen TC, Fang KH, Tsang YM
(2016) Adding concurrent chemotherapy to postoperative radio-
therapy improves locoregional control but not overall survival in
patients with salivary gland adenoid cystic carcinoma—a propen-
sity score matched study. Radiat Oncol 11:47. https://doi.org/10.1186/s13014-016-0617-7
35. Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti
A (2016) Adjuvant chemoradiotherapy versus with radiotherapy
alone for locally advanced salivary gland carcinoma among older
patients. Head Neck 38(6):863–870. https://doi.org/10.1002/hed.
24172
36. Spiro RH (1986) Salivary neoplasms: overview of a 35-year expe-
rience with 2,807 patients. Head Neck Surg 8(3):177–184. https://
doi.org/10.1002/hed.2890083009
37. Spiro RH, Armstrong J, Harrison L, Geller NL, Lin SY, Strong
EW (1989) Carcinoma of major salivary glands. Recent trends.
Arch Otolaryngol Head Neck Surg 115(3):316–321. https://doi.
org/10.1001/archotol.1989.01860270058015
38. Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW,
Fuks ZY (1990) Malignant tumors of major salivary gland origin.
A matched-pair analysis of the role of combined surgery and
postoperative radiotherapy. Arch Otolaryngol Head Neck Surg
116(3):290–293. https://doi.org/10.1001/archotol.1990.01870
30054008
39. Fu KK, Leibel SA, Levine ML, Friedlander LM, Boles R, Phillips
TL (1977) Carcinoma of the major and minor salivary glands:
analysis of treatment results and sites and causes of failures. Can-
cer 40(6):2882–2890. https://doi.org/10.1002/1097-0142(197712)
40:6%3c2882::aid-CNCR2820400618%3e3.0.CO;2-I
40. Fitzpatrick PJ, Theriault C (1986) Malignant salivary gland
tumors. Int J Radiat Oncol Biol Phys 12(10):1743–1747. https://
doi.org/10.1016/0360-3016(86)90314-7
41. Borthne A, Kjellevold K, Kaalhus O, Vermund H (1986) Saliv-
ary gland malignant neoplasms: treatment and prognosis. Int J
Radiat Oncol Biol Phys 12(10):747–754. https://doi.org/10.1016/
0360-3016(86)90314-7
42. Vander Poorten VL, Balm AJ, Hilgers CW, Keus RB, Hart AA
(1999) Prognostic factors for long term results of the treatment of patients with malignant submandibular gland
tumors. Cancer 85(10):2255–2264. https://doi.org/10.1002/
s13014-016-0617-7
43. Croonenborghs TM, Van Hevele J, Scheerlinck J, Nout E, Sch-
penaers J, Politis C (2020) A multicentre retrospective clinico-
histopathological review of 250 patients after parotidectomy. Int J
Oncol MaxillofacSurg 35(2):149–156. https://doi.org/10.1016/j.
joms.2019.03.963
44. Zernial O, Springer IN, Warnke P, Harle F, Risick C, Wiltfang J
(2007) Long-term recurrence rate of pleomorphic adenoma and
high-risk salivary gland malignancies. Head Neck Oncol 3:31.
https://doi.org/10.1186/1758-3284-3-31
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
https://doi.org/10.1016/j.joms.2005.03.006